Cheryl E. Balkman

Clinical application of the MEK inhibitor trametinib in dogs with oral squamous cell carcinoma

William P. Katt, Cheryl E. Balkman, Michael Byron, Patrick C. Carney et autres

Oral squamous cell carcinoma (OSCC) is a common and, if left untreated, deadly disease in dogs. The current standard of care involves wide-margin surgical excision of tumor tissue, which is frequently disfiguring. Surgical treatment can also be debilitating and lead to a …

us (code pays fourni par la source)

Clinical application of the MEK inhibitor trametinib in dogs with oral squamous cell carcinoma

William P. Katt, Cheryl E. Balkman, Michael Byron, Patrick C. Carney et autres

us (code pays fourni par la source)

The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma

William P. Katt, Cheryl E. Balkman, Scott D. Butler, Michael Byron et autres

Oral tumors are relatively common in dogs, and canine oral squamous cell carcinoma (COSCC) is the most prevalent oral malignancy of epithelial origin. COSCC is locally aggressive with up to 20% of patients showing regional or distant metastasis at the time of …

us, fi (code pays fourni par la source)

Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2

Nicola J. Mason, Laura Elizabeth Selmic, Audrey Ruple, Cheryl A. London et autres

A clinical trial in dogs with spontaneous osteosarcoma was performed to assess a recombinant Listeria expressing a chimeric human HER2 (ADXS31-164 c ) as an adjunctive vaccine strategy to prevent metastatic disease and determine immunological correlates of clinical outcome. A total of …

us, ca, au (code pays fourni par la source)

Novel approach to thoracoscopic removal of a mediastinal neuroendocrine tumour in a dog

Christopher D. Connolly, Ian H. Porter, Cheryl E. Balkman, Nicole J. Buote

Abstract An 8‐year‐old, female, spayed bloodhound mix was presented for a 9‐day history of right‐sided Horner's syndrome. Thoracic computed tomography revealed a right‐sided, 4.1 × 2.2 cm, round, soft tissue opacity located in the cranial aspect of the dorsal mediastinum ventral to …

us (code pays fourni par la source)

Retrospective evaluation of outpatient intravenous ketamine-lidocaine infusions for the palliation of cancer pain in dogs and cats

Kari E. Iocolano, Andrea L. Looney, Cheryl E. Balkman, Kelly R. Hume et autres

OBJECTIVE: To evaluate the clinical benefit and adverse events following outpatient intravenous (IV) ketamine-lidocaine (KL) infusions for palliation of cancer pain in dogs and cats. METHODS: Medical records from 15 years (2008 to 2023) were searched and data reviewed retrospectively. Animals were …

us (code pays fourni par la source)

Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas

Santiago Peralta, William P. Katt, Cheryl E. Balkman, Scott D. Butler et autres

us, fi (code pays fourni par la source)

Supplementary Figure 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Amy Kathleen LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger et autres

Supplementary Fig. 2 shows the walk-in pharmacokinetics, both measured results and simulated values, for dogs treated with oral sirolimus in preparation for the definitive adjuvant trial.

Supplementary Table 2 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Amy Kathleen LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger et autres

Supplementary Table 2 contains the summary comparison of both the Intent-to-treat and Per-protocol analyses of clinical outcomes for dogs enrolled in Standard of Care (SOC) and Standard of Care + sirolimus

Supplementary Table 3 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Amy Kathleen LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger et autres

Supplementary Table 3 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.

Supplementary Table 1 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Amy Kathleen LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger et autres

Supplementary Table 1 contains the inclusion and exclusion criteria for pet dogs considered for enrollment into the SOC and SOC + S clinical trial arms.

Supplementary Table 4 from Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

Amy Kathleen LeBlanc, Christina N. Mazcko, Aswini Cherukuri, Erika P. Berger et autres

Supplementary Table 4 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC + sirolimus clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.